Our Pricing

Mounjaro vs Saxenda: Clinical Comparison & UK Prescribing Guide

When you buy Mounjaro vs Saxenda online UK, understanding the clinical differences between tirzepatide and liraglutide is essential for making an informed choice. Both are MHRA-licensed injectable treatments for weight management, but they work through different mechanisms and produce different outcomes in clinical trials. At Cured Pharmacy, our UK-registered clinical team helps patients navigate these options with transparent pricing and expert guidance from superintendent pharmacist Tarun Kumar (GPhC 2233073).

How Mounjaro and Saxenda Work Differently

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, activating two separate hormone pathways that regulate appetite, blood sugar control, and energy metabolism [1]. This dual mechanism represents a significant advancement over single-pathway treatments, producing enhanced metabolic effects and greater weight reduction in head-to-head studies.

Saxenda (liraglutide) is a GLP-1 receptor agonist that mimics a single natural hormone involved in appetite regulation and glucose control [2]. Licensed in the UK since 2015, it's administered as a daily subcutaneous injection at doses up to 3.0mg. Liraglutide slows gastric emptying, increases satiety after meals, and reduces food intake through central nervous system pathways.

The key pharmacological difference lies in tirzepatide's additional GIP receptor activation, which appears to enhance insulin secretion, improve fat metabolism, and produce greater body weight reductions compared to GLP-1 agonism alone [1]. Clinical trials demonstrate this translates into measurably different outcomes for UK patients.

Clinical Trial Data: Mounjaro vs Saxenda Efficacy

In the SURPASS-3 trial, patients receiving Mounjaro 15mg achieved an average body weight reduction of 22.5% over 72 weeks — the highest weight loss observed in any obesity medication trial to date [1]. Even the lower 5mg dose produced average reductions of 15.0%, substantially exceeding results seen with earlier GLP-1 treatments.

The SCALE Obesity and Prediabetes trial, which established Saxenda's efficacy profile, showed average weight loss of 8.0% at 56 weeks in patients receiving liraglutide 3.0mg daily [2]. Approximately 63.2% of participants achieved at least 5% body weight reduction, meeting the primary endpoint for clinically meaningful weight loss.

While direct head-to-head trials between tirzepatide and liraglutide are limited, indirect comparisons suggest Mounjaro produces roughly 2-3 times greater weight reduction than Saxenda in similar patient populations [3]. However, individual response varies considerably, and your UK prescriber will consider your medical history, treatment goals, and tolerance when recommending the most suitable option.

What the Numbers Mean for UK Patients

For a patient weighing 100kg, the average 22.5% reduction with Mounjaro translates to approximately 22.5kg weight loss, whilst the 8.0% reduction with Saxenda represents about 8kg. These are average trial outcomes — individual results depend on adherence to treatment, lifestyle modifications, baseline metabolic health, and genetic factors that influence medication response.

Dosing Schedules and Administration

Mounjaro is administered once weekly via subcutaneous injection using a pre-filled KwikPen device. UK prescribers typically initiate treatment at 2.5mg weekly for four weeks, then escalate to 5mg for at least four weeks before considering further increases to 7.5mg, 10mg, 12.5mg, or the maximum 15mg dose [4]. This gradual titration minimises gastrointestinal side effects whilst allowing your body to adapt to the medication.

Saxenda requires daily subcutaneous injections, starting at 0.6mg and increasing by 0.6mg increments weekly until reaching the maintenance dose of 3.0mg daily [2]. The daily administration schedule demands consistent adherence, which some patients find more challenging than weekly injections, though others prefer the flexibility of adjusting doses more frequently if side effects occur.

From a practical standpoint, Mounjaro's weekly dosing often improves treatment adherence and fits more easily into busy lifestyles. However, Saxenda's daily injections allow for more immediate dose adjustments if you experience gastrointestinal symptoms, providing greater short-term control over side effect management.

Injection Technique and Pen Devices

Both medications use similar pre-filled pen injectors designed for subcutaneous administration into the abdomen, thigh, or upper arm. The injection process takes less than 10 seconds, and most UK patients report minimal discomfort. Your Cured Pharmacy clinical team provides detailed administration guidance, and both manufacturers offer video tutorials and patient support programmes to ensure proper technique.

Side Effects and Tolerability Profiles

Gastrointestinal side effects are the most common adverse events with both treatments. In clinical trials, nausea occurred in approximately 44% of Mounjaro patients and 39% of Saxenda patients, typically peaking during dose escalation phases and diminishing over subsequent weeks [1][2]. Diarrhoea, constipation, vomiting, and abdominal discomfort are also frequently reported but usually mild to moderate in severity.

Serious side effects are uncommon but require immediate medical attention. Both medications carry warnings about potential pancreatitis, gallbladder disease, and thyroid C-cell tumours (based on rodent studies, though human relevance remains uncertain) [4][5]. UK prescribers screen for contraindications including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 before prescribing either treatment.

Hypoglycaemia risk is generally low with both Mounjaro and Saxenda when used alone for weight management, but increases if you're taking concurrent diabetes medications such as insulin or sulphonylureas. Your UK prescriber will review all current medications during your clinical assessment to identify potential interactions and adjust doses accordingly.

Managing Common Side Effects

Most gastrointestinal symptoms can be minimised through dietary modifications: eating smaller, more frequent meals; avoiding high-fat foods; staying well-hydrated; and allowing adequate time between dose escalations. If side effects become intolerable, your prescriber may slow the titration schedule or reduce to the previous well-tolerated dose. Persistent severe symptoms warrant immediate clinical review.

Cost Comparison and UK Pricing

At Cured Pharmacy, Mounjaro is available from £135.00 per pen, with final pricing determined by your prescribed dose following clinical assessment by a UK prescriber. We maintain transparent upfront pricing — you'll see exact costs before completing your consultation, with no hidden fees or unexpected charges at checkout.

Treatment costs vary based on prescribed dose, treatment duration, and individual response. Weekly injectable treatments typically represent a higher monthly investment than daily options, but the superior efficacy profile and improved adherence with once-weekly dosing often provide better long-term value for UK patients committed to significant weight reduction.

All weight loss injections at Cured Pharmacy are genuine UK-licensed medications dispensed by our GPhC-registered pharmacy (9012511). We guarantee the lowest prices in the UK market whilst maintaining the highest standards of pharmaceutical care, with free clinical consultations completed in under three minutes and discreet next-day delivery available across the UK.

Who Should Choose Mounjaro vs Saxenda?

Mounjaro may be more suitable for UK patients seeking maximum weight reduction, those who prefer weekly rather than daily injections, or individuals who haven't achieved adequate results with earlier GLP-1 treatments like Saxenda or Wegovy. The dual-agonist mechanism offers enhanced efficacy for patients with significant weight to lose or those with concurrent metabolic conditions [1][3].

Saxenda remains an excellent option for patients who prefer daily dosing flexibility, those new to injectable weight loss treatments, or individuals seeking a well-established medication with extensive real-world safety data spanning nearly a decade of UK use [2]. The lower starting price point also makes it accessible for patients exploring injectable treatments for the first time.

Both treatments require commitment to lifestyle modifications including reduced-calorie diet and increased physical activity. UK prescribing guidelines specify these medications are licensed for adults with BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or dyslipidaemia [5]. Your Cured Pharmacy prescriber will assess your eligibility, medical history, current medications, and treatment goals during your free online consultation to recommend the most appropriate option.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.medicines.org.uk/emc/product/14713
5. National Institute for Health and Care Excellence. (2023). Liraglutide for managing overweight and obesity: Technology appraisal guidance [TA664]. Retrieved from https://www.nice.org.uk/guidance/ta664

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment, lifestyle modifications, and individual metabolic factors.